FZ002-037 / Guangzhou Fermion - LARVOL DELTA

A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile (clinicaltrials.gov) - P1 | N=86 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

First-in-human • New P1 trial • Infectious Disease

Fermion announces IND Approval of Non-Addictive Pain Relief Drug FZ008-145 by China NMPA (PRNewswire) - "Guangzhou Fermion Technology Co., Ltd...has announced today that China National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) application for its non-addictive pain relief drug FZ008-145....Alongside FZ008-145, the lead pipeline FZ002-037 has completed Phase I clinical trials and is poised to initiate Phase II concept validation POC trials, positioning it the second globally and the first in China clinical drug with the same target."

New trial • Pain